LANA PL
Alternative Names: LANA AS; LANA-PLLatest Information Update: 28 Feb 2025
At a glance
- Originator Antlia Bioscience
- Developer Antlia Bioscience; Karolinska Institute
- Class Antiasthmatics; Antihypertensives; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease; Pulmonary hypertension
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (Inhalation, Aerosol)
- 28 Feb 2025 No recent reports of development identified for preclinical development in Pulmonary-hypertension in USA (Inhalation, Aerosol)
- 28 Dec 2024 No recent reports of development identified for preclinical development in Asthma in USA (Inhalation, Aerosol)